Style | Citing Format |
---|---|
MLA | Dastar S, et al.. "Covid-19 Pandemic: Insights Into Genetic Susceptibility to Sars-Cov-2 and Host Genes Implications on Virus Spread, Disease Severity and Outcomes." Human Antibodies, vol. 30, no. 1, 2022, pp. 1-14. |
APA | Dastar S, Gharesouran J, Mortazavi D, Hosseinzadeh H, Kian SJ, Taheri M, Ghafourifard S, Jamali E, Rezazadeh M (2022). Covid-19 Pandemic: Insights Into Genetic Susceptibility to Sars-Cov-2 and Host Genes Implications on Virus Spread, Disease Severity and Outcomes. Human Antibodies, 30(1), 1-14. |
Chicago | Dastar S, Gharesouran J, Mortazavi D, Hosseinzadeh H, Kian SJ, Taheri M, Ghafourifard S, Jamali E, Rezazadeh M. "Covid-19 Pandemic: Insights Into Genetic Susceptibility to Sars-Cov-2 and Host Genes Implications on Virus Spread, Disease Severity and Outcomes." Human Antibodies 30, no. 1 (2022): 1-14. |
Harvard | Dastar S et al. (2022) 'Covid-19 Pandemic: Insights Into Genetic Susceptibility to Sars-Cov-2 and Host Genes Implications on Virus Spread, Disease Severity and Outcomes', Human Antibodies, 30(1), pp. 1-14. |
Vancouver | Dastar S, Gharesouran J, Mortazavi D, Hosseinzadeh H, Kian SJ, Taheri M, et al.. Covid-19 Pandemic: Insights Into Genetic Susceptibility to Sars-Cov-2 and Host Genes Implications on Virus Spread, Disease Severity and Outcomes. Human Antibodies. 2022;30(1):1-14. |
BibTex | @article{ author = {Dastar S and Gharesouran J and Mortazavi D and Hosseinzadeh H and Kian SJ and Taheri M and Ghafourifard S and Jamali E and Rezazadeh M}, title = {Covid-19 Pandemic: Insights Into Genetic Susceptibility to Sars-Cov-2 and Host Genes Implications on Virus Spread, Disease Severity and Outcomes}, journal = {Human Antibodies}, volume = {30}, number = {1}, pages = {1-14}, year = {2022} } |
RIS | TY - JOUR AU - Dastar S AU - Gharesouran J AU - Mortazavi D AU - Hosseinzadeh H AU - Kian SJ AU - Taheri M AU - Ghafourifard S AU - Jamali E AU - Rezazadeh M TI - Covid-19 Pandemic: Insights Into Genetic Susceptibility to Sars-Cov-2 and Host Genes Implications on Virus Spread, Disease Severity and Outcomes JO - Human Antibodies VL - 30 IS - 1 SP - 1 EP - 14 PY - 2022 ER - |